Utility of B-RAF DNA mutation in diagnosis and treatment of cancer
The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
1. A method of treating cancer in a subject, comprising:
isolating a DNA sample from a body fluid sample from the subject;
detecting whether a mutant B-RAF gene is present in the body fluid sample containing DNA from the subject, wherein the mutant B-RAF gene contains a B-RAF V600E mutation;
determining that the subject is likely suffering from cancer when the mutant B-RAF gene is present in the sample, wherein the cancer is melanoma, thyroid cancer, colorectal cancer, lung cancer, or neurocancer; and
administering a cancer therapy to the subject likely suffering from the cancer.
2. The method of claim 1 , wherein the body fluid sample is a blood, plasma, serum, or cerebral spinal fluid sample.
3. A method of treating a cancer based on a predicted outcome, comprising:
isolating a DNA sample from a body fluid sample from the subject;
quantifying an amount of a mutant B-RAF gene that is present in a body fluid sample containing DNA from a test subject suffering from the cancer, wherein the cancer is melanoma, thyroid cancer, colorectal cancer, lung cancer, or neurocancer;
predicting, when the mutant B-RAF gene is present in the sample, that the test subject has a lower probability to survive or to be a responder to cancer therapy than a control subject who suffers from cancer but does not have the mutant B-RAF gene; and
administering a cancer therapy to the subject who suffers from cancer but does not have the mutant B-RAF gene,
wherein the mutant B-RAF gene contains a B-RAF V600E mutation.
4. The method of claim 3 , wherein the tissue sample is a paraffin-embedded tissue sample, and the body fluid sample is a blood, plasma, serum, or cerebral spinal fluid sample.
5. The method of claim 3 , wherein the cancer therapy is a biochemotherapy.
6. The method of claim 3 , wherein the sample is obtained from the test subject prior to or following the therapy.
7. A method of monitoring the treatment of a cancer, comprising:
isolating a DNA sample from a body fluid sample from the subject;
quantifying an amount of a mutant B-RAF gene that is present in a first body fluid sample containing DNA from a subject suffering from the cancer prior to treating the subject with a cancer therapy, wherein the cancer is melanoma, thyroid cancer, colorectal cancer, lung cancer, or neurocancer;
quantifying an amount of a mutant B-RAF gene is present in a second body fluid tissue sample containing DNA from the subject after treating the subject with the cancer therapy;
determining that the subject is likely to respond to the therapy when the mutant B-RAF gene is present in a lower amount in the second sample as compared to the first sample; and
administering additional cancer therapy to the subject that is likely to respond to the therapy,
wherein the mutant B-RAF gene contains a B-RAF V600E mutation.
8. The method of claim 7 , wherein the body fluid sample is a blood, plasma, serum, or cerebral spinal fluid sample.
9. The method of claim 7 , wherein the cancer therapy is a biochemotherapy.
10. A method of treating a cancer in a subject based on the status of the cancer, comprising:
isolating a DNA sample from a body fluid sample from the subject;
quantifying an amount of a mutant B-RAF gene that is present in a first body fluid sample containing DNA from a subject suffering from the cancer at a first time point;
quantifying an amount of a mutant B-RAF gene is present in a second body fluid sample containing DNA from the subject at a second time point subsequent to the first time point;
determining (i) that the cancer has likely progressed in the subject when the mutant B-RAF gene is present in a higher amount in the second sample as compared to the first sample or (ii) that the cancer has likely regressed in the subject when the mutant B-RAF gene is present in a lower amount in the second sample as compared to the first sample, wherein the cancer is melanoma, thyroid cancer, colorectal cancer, lung cancer, or neurocancer; and
administering a cancer therapy to the subject determined to have regressed cancer,
wherein the mutant B-RAF gene contains a B-RAF V600E mutation.